Harbour BioMed partnered with Mount Sinai Health System of New York City to discover novel antibodies that treat/prevent oncology and immunology diseases, starting with a COVID-19 mAb. HBM will use its H2L2 Harbour Mice® platform to generate mAbs that treat people who contract the virus or for prophylactic use in healthcare workers or other people exposed to the virus. The antibody will aim to block the virus from infecting cells. Harbour's discovery operations are in Rotterdam, its headquarters in Boston and other operations in Suzhou and Shanghai.

Mount Sinai is New York City's largest medical provider with over 7,000 doctors on staff. Its collaboration with Harbour was described as a combination of Harbour's discovery expertise with the hospital chain's translational medical abilities. The hospital also includes Mount Sinai Innovation Partners (MSIP), which is in charge of commercializing Mount Sinai discoveries and inventions. MSIP claims to have a full suite of services available to bring new products to the market.

“We are pleased to be able to collaborate with HBM at this time and leverage our experience in therapeutic antibody generation as well as the viral expertise of the Microbiology Department with the unique human antibody producing mice from Harbour,” said Professor Thomas Moran, PhD, Director, Center for Therapeutic Antibody Development (CTAD) at Icahn School of Medicine at Mount Sinai.

“This is a unique collaboration that will give HBM access to Mount Sinai’s innovative research driven from its clinical practices. The agreement demonstrates HBM’s commitment to develop novel medicines and foster fast-track innovative research. We will push the boundaries of science and the development of new medicines that will ultimately translate into better treatments for patients,” said Jingsong Wang, MD, PhD, Founder, Chairman & Chief Executive Officer of HBM.

“The relationship with HBM is yet another opportunity for Mount Sinai to develop new treatments for significant diseases and conditions,” said Erik Lium, PhD, President, Mount Sinai Innovation Partners. “This work will bring Mount Sinai’s innovation ecosystem one step closer to the drug development process.”

The Mount Sinai Health System includes eight hospitals, a leading medical school, and a large network of ambulatory practices throughout the greater New York region.

Harbour BioMed uses its platforms to discover novel drugs for its own use and for partners as well. The company has formed relationships with with China biopharmas BeiGene and Innovent as well as other global companies.

See our other articles on Harbour BioMed.

Disclosure: none.